Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1083-1096

  Li, Lei ^a   Xiang, Dongxi ^b   Shigdar, Sarah ^b   Yang, Wenrong ^c   Li, Qiong ^b   Lin, Jia ^d   Liu, Kexin ^a   Duan, Wei ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DEAKIN UNIVERSITY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Aptamer; Curcumin; EpCAM; PLGA lecithin PEG nanoparticles; Targeted drug delivery

Indexed keywords

APTAMER; CURCUMIN; LIPID; MACROGOL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; RNA; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; NANOCONJUGATE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; TIMED DRUG RELEASE; ZETA POTENTIAL; ADENOCARCINOMA; ANIMAL; CELL SURVIVAL; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HT 29 CELL LINE; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL ADHESION MOLECULES; CELL SURVIVAL; COLORECTAL NEOPLASMS; CURCUMIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HEK293 CELLS; HT29 CELLS; HUMANS; LACTIC ACID; LECITHINS; MALE; NANOCONJUGATES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896879273     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S59779     Document Type: Article

References (37)

1. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6(4): 1041-1051.
2. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA- PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-876.
3. Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30(8): 1627-1634.
4. Zheng Y, Yu B, Weecharangsan W, et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm. 2010;390(2):234-241.
5. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668-7672.
6. Shigdar S, Ward AC, De A, Yang CJ, Wei M, Duan W. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br J Haematol. 2011;155(1):3-13.
7. Shigdar S, Lin J, Li Y, et al. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Ther Deliv. 2012;3(2): 227-244.
8. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18): 2081-2087.
9. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79(3):330-338.
10. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012; 17(1-2):71-80.
11. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955-1968.
12. Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm. 2009;382(1-2):254-261.
13. Nair KL, Thulasidasan AK, Deepa G, Anto RJ, Kumar GS. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm. 2012;425(1-2):44-52.
14. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One. 2012;7(3):e32616.
15. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1-16.
16. Bouarab L, Maherani B, Kheirolomoom A, et al. Influence of lecithin-lipid composition on physico-chemical properties of nanoliposomes loaded with a hydrophobic molecule. Colloids Surf B Biointerfaces. 2013;115C:197-204.
17. Aravind A, Jeyamohan P, Nair R, et al. AS1411 aptamer tagged PLGA- lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012;109(11):2920-2931.
18. Shigdar S, Qiao L, Zhou SF, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013;330(1):84-95.
19. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351(1): 19-29.
20. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs. 2008;68(6):771-789.
21. Herzog TJ, Pothuri B. Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol. 2006;3(11):604-611.
22. Langer R. Drug delivery. Drugs on target. Science. 2001; 293(5527):58-59.
23. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5): 387-422.
24. Chan VS. Nanomedicine: An unresolved regulatory issue. Regul Toxicol Pharmacol. 2006;46(3):218-224.
25. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv. 2006;3(3):311-324.
26. Kim JY, Kim JK, Park JS, Byun Y, Kim CK. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials. 2009;30(29):5751-5756.
27. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3-4):223-230.
28. Grabovac V, Bernkop-Schnürch A. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine. Drug Dev Ind Pharm. 2007;33(7): 767-774.
29. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010-8020.
30. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release. 2006;113(1):38-42.
31. Khalil NM, do Nascimento TC, Casa DM, et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces. 2013;101: 353-360.
32. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600-1603.
33. Fenske DB, MacLachlan I, Cullis PR. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 2002;346:36-71.
34. Fang RH, Hu CM, Zhang L. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther. 2012;12(4):385-389.
35. Patil YB, Toti US, Khdair A, Ma L, Panyam J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials. 2009;30(5):859-866.
36. Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 2008;4(6): 1752-1761.
37. Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, Limtrakul P. Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin. 2012;33(6):823-831.